EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

20. Is a certificate of analysis enough to approve a compounded GLP-1 supplier?

Dose Diligence research deskSection 01 · Page 20 of 34Last updated 17 Nov 2026

No. Treat a certificate of analysis as one document addressing specified material or tests—not as an overall approval of the finished product, facility or legal route. FDA’s statutory comparison identifies a valid certificate of analysis as one of the bulk-substance conditions, alongside other requirements. (fda.gov)

Proposed quality-review questions:

  • Does the certificate cover raw ingredient or finished preparation?
  • Does its lot identifier match the supplied material?
  • Which laboratory performed which tests, and when?
  • What methods, acceptance criteria and limitations apply?
  • What information addresses finished-product strength, sterility and other relevant attributes?
  • What supports the assigned storage conditions and beyond-use period?
  • Who reviews deviations and authorizes release?

Do not turn this checklist into an assertion that every supplier must publish identical testing records. Have a qualified quality professional assess what evidence is appropriate to the pathway and preparation.

Independent legal check remains necessary: testing cannot establish a statutory permission that the proposed arrangement otherwise lacks.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding
Section sources →